The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

RBC Capital maintained a Sector Perform rating on Regeneron, with a price target of $662, following challenges in the itepekimab program. A survey conducted by RBC Capital indicated investor interest ...

In April 2025, Sanofi and Regeneron announced that their Phase III AERIFY-1 trial evaluating the fully human monoclonal antibody itepekimab in former smokers with inadequately controlled chronic ...

NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ( ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.

Piper Sandler's analysis indicates that biologics remain complementary to OHTUVAYRE treatment, while the recent failure of itepekimab (IL-33) further validates OHTUVAYRE's broad therapeutic effect.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...